CRNC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cerence Inc (CRNC) is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. While the company has shown significant revenue growth, its declining net income, EPS, and bearish technical indicators suggest limited immediate upside potential. Additionally, insider selling and mixed analyst ratings further weigh against a buy recommendation.
The technical indicators for CRNC are bearish. The moving averages (SMA_200 > SMA_20 > SMA_5) indicate a downward trend. The RSI is neutral at 22.863, and the MACD histogram is above 0 but contracting. Key support and resistance levels show the stock is near its support level (S1: 6.569), with limited upward momentum. Overall, the technical setup does not favor a strong buy.
Hedge funds are increasing their holdings, with a 348.02% increase in buying over the last quarter. Gross margin improved significantly, up 35.12% YoY to 86.33%. Revenue also increased by 126.10% YoY in Q1 2026.
Insiders are selling heavily, with an 8776.61% increase in selling over the last month. Net income dropped significantly (-78.43% YoY), and EPS declined by -78.95% YoY. Analysts have lowered price targets, citing limited growth and profitability. No recent news or congress trading data to provide additional support for a buy decision.
In Q1 2026, Cerence reported a 126.10% YoY increase in revenue to $115.08M. However, net income dropped to -$5.24M (-78.43% YoY), and EPS declined to -$0.12 (-78.95% YoY). Despite an improved gross margin of 86.33% (+35.12% YoY), the overall financial performance reflects significant profitability challenges.
Analysts have mixed views on CRNC. Goldman Sachs lowered its price target to $8 from $11, maintaining a Neutral rating, citing limited growth and profitability despite progress on agentic AI. TD Cowen also reduced its price target to $12 from $13, maintaining a Hold rating, highlighting a noisy financial outcome and potential EBITDA shortfall for the rest of FY26.
